Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interleukin 24 gene therapy in patients with advanced tumours.

Trial Profile

Interleukin 24 gene therapy in patients with advanced tumours.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2014

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Interleukin 24 gene therapy-MultiVir (Primary)
  • Indications Solid tumours
  • Focus Pharmacodynamics
  • Sponsors MultiVir
  • Most Recent Events

    • 03 Mar 2014 Title is not official.
    • 03 Mar 2014 New trial record
    • 14 Feb 2014 Top-line results of a presentation at the Leerink Global Healthcare conference reported in a MultiVir media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top